A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
Patients with the chronic liver disease NASH must now wait even longer for an approved…
Genfit is poised to become the first company to get a treatment for NASH to…
The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for…
After some big failures from its top competitors earlier this year, French company Genfit has…
The FDA has cleared Genfit to kick off clinical trials to see if its NASH…
Christmas might have passed, but we have more videos for you to watch on a…
Elafibranor, Genfit's lead candidate, will continue its march towards the market with the added boost of…
Biotech is the best source of innovation in R&D, making its companies the darlings of…
After we reviewed NASH earlier this year, Genfit's CSO, Dean Hum, came to speak at…
Genfit has announced that closing of enrollment will be delayed up to 6 months. Will…
Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining…